Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
HHKEX:225221.18
HKD
-0.82
(-3.73%)
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
HKEX:2252
(Hong Kong Exchange)
Recent
price
21.18
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research, development, design, manufacture, and sale of advanced surgical robots and intelligent surgical solutions. Its core products include the Toumai laparoscopic surgical robot, which supports urologic, gynecologic, thoracic, and general surgeries; the SkyWalker orthopedic surgical robot for knee and hip arthroplasty; the R-One vascular interventional surgical robot for coronary angioplasty; the iSR’obot Mona Lisa robotic transperineal prostate biopsy system; DFVision 3D electronic laparoscope used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; as well as spine surgical robots, trans-bronchial surgical robots for diagnosis and treatment, and TAVR surgical robots for heart valve replacement. The company manufactures robot parts, assembles, and distributes these devices while conducting extensive research and development. Founded in 2014 and headquartered in Shanghai, China, MicroPort MedBot operates globally and is a subsidiary of Shanghai Latent Artificial Intelligence Co., Ltd. In the last 1-2 years, Shanghai MicroPort MedBot has achieved major development milestones including surpassing 130 global orders for its robotic-assisted surgical systems with over 50 Toumai systems installed worldwide, supporting more than 10,000 procedures. In 2025, the company enabled the world’s first 5G ultra telerobotics remote liver cancer resection and was the first to receive regulatory approval for full-spectrum remote surgical applications, facilitating Europe’s first robot-assisted telesurgery with ultra-low latency networks. The SkyWalker orthopedic surgical robot received market approval from Health Canada as part of its strategic expansion into key international markets. Additionally, the Toumai single-arm surgical robot completed the first gynecological registered clinical trial and obtained multiple regulatory clearances including NMPA multi-department approvals and EU CE certification for the DFVision endoscope. Organizationally, the company has undergone substantial board restructuring to support its global growth trajectory. MicroPort MedBot’s industry focus encompasses five major surgical specialties: laparoscopic, orthopedic, panvascular, natural orifice, and percutaneous surgical procedures. The company targets hospitals and surgical centers worldwide, with regulatory and commercial footprints extending over 30 countries and regions. Its products integrate optics, mechanics, electronics, software, control algorithms, and precision imaging to deliver intelligent surgical solutions. The company is positioned as a leader in robotic surgery innovation, dedicated to improving surgical precision and expanding remote surgical capabilities using cutting-edge technologies in robotics and telecommunications. Shanghai MicroPort MedBot’s product portfolio and ongoing innovations reinforce its role in transforming surgical practice through platform-based multi-disciplinary robotic systems, supported by a robust R&D, clinical trial, and regulatory framework. Its latest advances in telesurgery and regulatory milestones underline a strategic shift towards connected and remote surgery platforms to meet growing global demand for intelligent surgical technologies.